APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Romiplostim

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Romiplostim Market Outlook and Growth Opportunities 2026

Report ID 174033400422 December 2025191 pages

Choose your research edition.

Industry ResearchRomiplostim Industry Research Report 2026105 pages · $2,950 USDIndustry Growth & TrendsGlobal Romiplostim Industry Growth and Trends Forecast to 203261 pages · $3,450 USDMarket StructureGlobal Romiplostim Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032177 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Romiplostim Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Romiplostim Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Romiplostim market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Romiplostim is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Romiplostim is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Romiplostim is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Romiplostim market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Romiplostim market include AMGEN. among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Romiplostim market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Romiplostim and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Romiplostim revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Romiplostim market.

Romiplostim Segment by Company

AMGEN

Romiplostim Segment by Type

250μg/ 0.5 mL

500μg/ 1 mL

Romiplostim Segment by Application

Adults

Pediatric patients

Romiplostim Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Romiplostim status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Romiplostim key companies, revenue, market share, and recent developments.

3. To split the Romiplostim breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Romiplostim market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Romiplostim significant trends, drivers, influence factors in global and regions.

6. To analyze Romiplostim competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Romiplostim market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Romiplostim and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Romiplostim.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Romiplostim industry.

Chapter 3: Detailed analysis of Romiplostim company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Romiplostim in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Romiplostim in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Romiplostim Industry Trends Table 2. Romiplostim Industry Drivers Table 3. Romiplostim Industry Opportunities and Challenges Table 4. Romiplostim Industry Restraints Table 5. Global Romiplostim Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Romiplostim Revenue Share by Company (2021-2026) Table 7. Global Romiplostim Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Romiplostim Key Company Manufacturing Base & Headquarters Table 9. Global Romiplostim Company, Product Type & Application Table 10. Global Romiplostim Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Romiplostim by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of 250μg/ 0.5 mL Table 15. Significant Companies of 500μg/ 1 mL Table 16. Global Romiplostim Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Romiplostim Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Romiplostim Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Romiplostim Sales Value Share by Type (2021-2026) Table 20. Global Romiplostim Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Adults Table 22. Significant Companies of Pediatric patients Table 23. Global Romiplostim Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Romiplostim Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Romiplostim Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Romiplostim Sales Value Share by Application (2021-2026) Table 27. Global Romiplostim Sales Value Share by Application (2027-2032) Table 28. Global Romiplostim Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Romiplostim Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Romiplostim Sales Value Share by Region (2021-2026) Table 31. Global Romiplostim Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Romiplostim Sales Value Share by Region (2027-2032) Table 33. Global Romiplostim Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Romiplostim Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Romiplostim Sales Value Market Share by Country (2021-2026) Table 36. Global Romiplostim Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Romiplostim Sales Value Market Share by Country (2027-2032) Table 38. AMGEN Company Information Table 39. AMGEN Business Overview Table 40. AMGEN Romiplostim Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. AMGEN Romiplostim Product Portfolio Table 42. AMGEN Recent Development Table 43. Research Programs/Design for This Report Table 44. Authors List of This Report Table 45. Secondary Sources Table 46. Primary Sources List of Figures Figure 1. Romiplostim Product Image Figure 2. Global Romiplostim Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Romiplostim Market Size (2021-2032) & (US$ Million) Figure 4. Global Romiplostim Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. 250μg/ 0.5 mL Image Figure 8. 500μg/ 1 mL Image Figure 9. Global Romiplostim Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Romiplostim Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Romiplostim Sales Value Share by Type (2021-2032) Figure 12. Adults Image Figure 13. Pediatric patients Image Figure 14. Global Romiplostim Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Romiplostim Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Romiplostim Sales Value Share by Application (2021-2032) Figure 17. Global Romiplostim Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Romiplostim Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Romiplostim Sales Value (2021-2032) & (US$ Million) Figure 20. North America Romiplostim Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Romiplostim Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Romiplostim Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Romiplostim Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Romiplostim Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Romiplostim Sales Value (2021-2032) & (US$ Million) Figure 26. South America Romiplostim Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Romiplostim Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Romiplostim Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Romiplostim Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Romiplostim Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Romiplostim Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • 250μg/ 0.5 mL
  • 500μg/ 1 mL
Applications
  • Adults
  • Pediatric patients
Companies covered
  • AMGEN

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Romiplostim Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Romiplostim Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Romiplostim Market Dynamics
  1. 2.1 Romiplostim Industry Trends
  2. 2.2 Romiplostim Industry Drivers
  3. 2.3 Romiplostim Industry Opportunities and Challenges
  4. 2.4 Romiplostim Industry Restraints
3 Romiplostim Market by Company
  1. 3.1 Global Romiplostim Company Revenue Ranking in 2025
  2. 3.2 Global Romiplostim Revenue by Company (2021-2026)
  3. 3.3 Global Romiplostim Company Ranking (2024-2026)
  4. 3.4 Global Romiplostim Company Manufacturing Base and Headquarters
  5. 3.5 Global Romiplostim Company Product Type and Application
  6. 3.6 Global Romiplostim Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Romiplostim Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Romiplostim Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Romiplostim Market by Type
  1. 4.1 Romiplostim Type Introduction
  2. 4.1.1 250μg/ 0.5 mL
  3. 4.1.2 500μg/ 1 mL
  4. 4.2 Global Romiplostim Sales Value by Type
  5. 4.2.1 Global Romiplostim Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Romiplostim Sales Value by Type (2021-2032)
  7. 4.2.3 Global Romiplostim Sales Value Share by Type (2021-2032)
5 Romiplostim Market by Application
  1. 5.1 Romiplostim Application Introduction
  2. 5.1.1 Adults
  3. 5.1.2 Pediatric patients
  4. 5.2 Global Romiplostim Sales Value by Application
  5. 5.2.1 Global Romiplostim Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Romiplostim Sales Value by Application (2021-2032)
  7. 5.2.3 Global Romiplostim Sales Value Share by Application (2021-2032)
6 Romiplostim Regional Value Analysis
  1. 6.1 Global Romiplostim Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Romiplostim Sales Value by Region (2021-2032)
  3. 6.2.1 Global Romiplostim Sales Value by Region: 2021-2026
  4. 6.2.2 Global Romiplostim Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Romiplostim Sales Value (2021-2032)
  7. 6.3.2 North America Romiplostim Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Romiplostim Sales Value (2021-2032)
  10. 6.4.2 Europe Romiplostim Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Romiplostim Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Romiplostim Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Romiplostim Sales Value (2021-2032)
  16. 6.6.2 South America Romiplostim Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Romiplostim Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Romiplostim Sales Value Share by Country, 2025 VS 2032
7 Romiplostim Country-level Value Analysis
  1. 7.1 Global Romiplostim Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Romiplostim Sales Value by Country (2021-2032)
  3. 7.2.1 Global Romiplostim Sales Value by Country (2021-2026)
  4. 7.2.2 Global Romiplostim Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Romiplostim Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Romiplostim Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Romiplostim Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Romiplostim Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Romiplostim Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Romiplostim Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Romiplostim Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Romiplostim Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Romiplostim Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Romiplostim Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Romiplostim Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Romiplostim Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Romiplostim Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Romiplostim Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Romiplostim Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Romiplostim Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Romiplostim Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Romiplostim Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Romiplostim Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Romiplostim Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Romiplostim Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Romiplostim Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Romiplostim Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Romiplostim Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Romiplostim Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Romiplostim Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Romiplostim Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Romiplostim Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Romiplostim Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Romiplostim Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Romiplostim Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Romiplostim Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Romiplostim Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Romiplostim Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Romiplostim Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Romiplostim Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Romiplostim Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Romiplostim Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Romiplostim Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Romiplostim Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Romiplostim Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Romiplostim Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Romiplostim Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Romiplostim Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Romiplostim Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Romiplostim Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Romiplostim Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Romiplostim Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Romiplostim Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Romiplostim Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Romiplostim Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Romiplostim Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Romiplostim Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Romiplostim Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Romiplostim Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Romiplostim Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Romiplostim Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Romiplostim Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Romiplostim Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Romiplostim Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Romiplostim Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Romiplostim Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Romiplostim Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Romiplostim Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Romiplostim Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Romiplostim Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Romiplostim Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Romiplostim Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Romiplostim Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Romiplostim Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Romiplostim Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Romiplostim Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Romiplostim Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Romiplostim Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Romiplostim Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Romiplostim Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Romiplostim Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Romiplostim Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Romiplostim Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Romiplostim Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Romiplostim Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Romiplostim Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Romiplostim Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Romiplostim Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AMGEN
  2. 8.1.1 AMGEN Company Information
  3. 8.1.2 AMGEN Business Overview
  4. 8.1.3 AMGEN Romiplostim Revenue and Gross Margin (2021-2026)
  5. 8.1.4 AMGEN Romiplostim Product Portfolio
  6. 8.1.5 AMGEN Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst